Trial Profile
A Randomized, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of Three Formulations of Bevacizumab (CT-P16, EU-approved Avastin and US-licensed Avastin) in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Jul 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Colorectal cancer
- Focus Pharmacokinetics
- Sponsors Celltrion
- 09 Mar 2019 Primary endpoint (Pharmacokinetics: maximum serum concentration (Cmax)) has been met, according to the results published in the BioDrugs
- 09 Mar 2019 Primary endpoint (Pharmacokinetics: AUC from time zero to the last quantifiable concentration (AUClast)) has been met, according to the results published in the BioDrugs
- 09 Mar 2019 Primary endpoint (Pharmacokinetics: Area under the concentration-time curve from time zero to infinity) has been met, according to the results published in the BioDrugs